Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):457–462. doi: 10.1038/sj.bjc.6690715

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck

C Couteau 1, N Chouaki 1, S Leyvraz 3, D Oulid-Aissa 2, A Lebecq 2, C Domenge 1, V Groult 2, S Bordessoule 3, F Janot 1, M De Forni 1, J-P Armand 1
PMCID: PMC2362927  PMID: 10507770

Abstract

This study was designed to evaluate the activity, safety and tolerance of docetaxel (D) in a selected population with metastatic squamous cell carcinoma of the head and neck (SCCHN). Twenty-four patients with no prior palliative therapy were enrolled and received D 100 mg m−2 by 1 h of infusion, every 3 weeks. All but two patients had been evaluated for efficacy on lung metastatic sites. No prophylactic administration of anti-emetics or growth factors was given. A pharmacokinetic study was performed in 22 patients. Twenty-one patients were assessable for response and 24 for toxicity. One hundred and four cycles were administered with a median of 4.5 (range 1–9) per patient. The median cumulative dose was 449 mg m−2. Partial responses were achieved in five patients with a median duration of 18.7 weeks (range 13.1–50.3). The overall response rate was 20.8% with a median duration of 11.0 weeks (range 2.4–52.6). The most frequent side-effect was neutropenia (79.2% grade IV) but with a short duration (median 4 days) and no febrile neutropenia. The incidence of moderate/severe fluid retention was 29.2% with one treatment discontinuation. Other toxicities (all grades) were common (skin 75%, asthenia 50%, infection 29.2%, nausea 16.7%, diarrhoea 12.5%, stomatitis 16.7%, vomiting 8.3% and HSR 8.3%). A mean clearance of 19.6 l h−1 m−2 and an area under the curve of 6.00 μg ml−1 h−1 was found in the pharmacokinetic analysis. Docetaxel is active in this selected population with metastatic SCCHN, with a good tolerance. © 1999 Cancer Research Campaign

Keywords: docetaxel, head and neck carcinoma, phase II trial

Full Text

The Full Text of this article is available as a PDF (62.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bissery M. C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991 Sep 15;51(18):4845–4852. [PubMed] [Google Scholar]
  2. Bissett D., Setanoians A., Cassidy J., Graham M. A., Chadwick G. A., Wilson P., Auzannet V., Le Bail N., Kaye S. B., Kerr D. J. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 1993 Feb 1;53(3):523–527. [PubMed] [Google Scholar]
  3. Braakhuis B. J., Kegel A., Welters M. J. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett. 1994 Jun 30;81(2):151–154. doi: 10.1016/0304-3835(94)90196-1. [DOI] [PubMed] [Google Scholar]
  4. Bruno R., Hille D., Riva A., Vivier N., ten Bokkel Huinnink W. W., van Oosterom A. T., Kaye S. B., Verweij J., Fossella F. V., Valero V. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan;16(1):187–196. doi: 10.1200/JCO.1998.16.1.187. [DOI] [PubMed] [Google Scholar]
  5. Burris H., Irvin R., Kuhn J., Kalter S., Smith L., Shaffer D., Fields S., Weiss G., Eckardt J., Rodriguez G. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993 May;11(5):950–958. doi: 10.1200/JCO.1993.11.5.950. [DOI] [PubMed] [Google Scholar]
  6. Catimel G., Vermorken J. B., Clavel M., de Mulder P., Judson I., Sessa C., Piccart M., Bruntsch U., Verweij J., Wanders J. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994 Jul;5(6):543–547. doi: 10.1093/oxfordjournals.annonc.a058910. [DOI] [PubMed] [Google Scholar]
  7. Catimel G., Verweij J., Mattijssen V., Hanauske A., Piccart M., Wanders J., Franklin H., Le Bail N., Clavel M., Kaye S. B. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994 Jul;5(6):533–537. doi: 10.1093/oxfordjournals.annonc.a058908. [DOI] [PubMed] [Google Scholar]
  8. Dreyfuss A. I., Clark J. R., Norris C. M., Rossi R. M., Lucarini J. W., Busse P. M., Poulin M. D., Thornhill L., Costello R., Posner M. R. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996 May;14(5):1672–1678. doi: 10.1200/JCO.1996.14.5.1672. [DOI] [PubMed] [Google Scholar]
  9. Extra J. M., Rousseau F., Bruno R., Clavel M., Le Bail N., Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993 Mar 1;53(5):1037–1042. [PubMed] [Google Scholar]
  10. Forastiere A. A., Neuberg D., Taylor S. G., 4th, DeConti R., Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Natl Cancer Inst Monogr. 1993;(15):181–184. [PubMed] [Google Scholar]
  11. Gandia D., Wibault P., Guillot T., Bensmaine A., Armand J. P., Marandas P., Luboinski B., Cvitkovic E. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck. 1993 Jan-Feb;15(1):8–15. doi: 10.1002/hed.2880150103. [DOI] [PubMed] [Google Scholar]
  12. Gebbia V., Testa A., Cannata G., Gebbia N. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer. 1996 May;32A(5):901–902. doi: 10.1016/0959-8049(96)00002-0. [DOI] [PubMed] [Google Scholar]
  13. Gebbia V., Testa A., Valenza R., Zerillo G., Restivo S., Ingria F., Cannata G., Gebbia N. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 1993;29A(9):1358–1359. doi: 10.1016/0959-8049(93)90095-w. [DOI] [PubMed] [Google Scholar]
  14. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1998. CA Cancer J Clin. 1998 Jan-Feb;48(1):6–29. doi: 10.3322/canjclin.48.1.6. [DOI] [PubMed] [Google Scholar]
  15. Pazdur R., Newman R. A., Newman B. M., Fuentes A., Benvenuto J., Bready B., Moore D., Jr, Jaiyesimi I., Vreeland F., Bayssas M. M. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst. 1992 Dec 2;84(23):1781–1788. doi: 10.1093/jnci/84.23.1781. [DOI] [PubMed] [Google Scholar]
  16. Recondo G., Armand J. P., Tellez-Bernal E., Domenge C., Belehradek M., De Vathaire F., Wibault P., Richard J. M., Cvitkovic E. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope. 1991 May;101(5):494–501. doi: 10.1288/00005537-199105000-00009. [DOI] [PubMed] [Google Scholar]
  17. Riou J. F., Naudin A., Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 1992 Aug 31;187(1):164–170. doi: 10.1016/s0006-291x(05)81474-3. [DOI] [PubMed] [Google Scholar]
  18. Schornagel J. H., Verweij J., de Mulder P. H., Cognetti F., Vermorken J. B., Cappelaere P., Armand J. P., Wildiers J., Clavel M., Kirkpatrick A. A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1992 Mar;3(3):223–226. doi: 10.1093/oxfordjournals.annonc.a058156. [DOI] [PubMed] [Google Scholar]
  19. Smith R. E., Thornton D. E., Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol. 1995 Jun;22(3 Suppl 6):41–46. [PubMed] [Google Scholar]
  20. Tomiak E., Piccart M. J., Kerger J., Lips S., Awada A., de Valeriola D., Ravoet C., Lossignol D., Sculier J. P., Auzannet V. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994 Jul;12(7):1458–1467. doi: 10.1200/JCO.1994.12.7.1458. [DOI] [PubMed] [Google Scholar]
  21. Verweij J. Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Anticancer Drugs. 1995 Jul;6 (Suppl 4):19–24. doi: 10.1097/00001813-199507004-00004. [DOI] [PubMed] [Google Scholar]
  22. Vokes E. E., Awan A. M., Weichselbaum R. R. Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug;5(4):753–767. [PubMed] [Google Scholar]
  23. Vokes E. E., Weichselbaum R. R., Lippman S. M., Hong W. K. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184–194. doi: 10.1056/NEJM199301213280306. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES